Board

Indipendent Director

Marta Bavasso graduated with a degree in Law from the University of Florence in 1993 including LLM education in EU Law and Institutions, EU Competition Law, International Commercial Law from the University College London. Qualified to practice as an attorney since 1997, she has worked for important national and international law firms, including MacKenzie Mills (currently Withersworldwide), Ernst &Young and Chiomenti for which she has followed relevant M&A transactions, joint ventures, private equity, fund structuring, IPOs, ICT practices of various nature, in different sectors. From 2000 to 2005 she worked as in-house legal counsel in the M&A department of Enel S.p.A. and, subsequently, in the start-up of H3G S.p.A. (later Wind Tre S.p.A.) – Group Hutchinson Whampoa Limited (HWL). In 2019 she launched, with other funding partners, a new law firm IPG Lex (currently IPG Lex&Tax-Studio Legale Tributario), as partner for corporate-m&a-private equity and TMT. Since February 2022 she is funding partner of the law firm Gambino-Scanzano-Pesce-Bavasso, with offices in Rome/Milan, and responsible for corporate-m&a-private equity and TMT. She is currently board member of Ericsson Telecomunicazioni S.p.A and independent board member of Generalfinance S.p.A. (GF – BIT).

.

Indipendent Director

Roberto Ferraresi graduated with honors in Business Administration at Bocconi University in Milan. Mr. Ferraresi started his career at UBS Investment bank in London in 1998. He then joined PAI partners in 2004 where, as a partner, he was actively involved in investment deals of more than €700 million. Mr. Ferraresi became board member of both private and listed companies. Since January 2018 he is founder and CEO of The Equity Club , a private equity initiative in the form of club deal, promoted together with Mediobanca and counting more than 90 investors among the most prominent families in Italy.

Born in Dairago (MI) in 1964, she graduated in Economia Aziendale summa cum laude from Università Commerciale Luigi Bocconi, Milan in 1987. From 1987 to 1990, Ms. Calloni worked as a business analyst at Memorex Telex in Milan, London and New York. In 1992, she obtained her M.B.A. with honors at the Leonard Stern School of Business, New York University. Upon graduation, she was hired by the investment bank Merrill Lynch in New York where she initially worked as Associate in Investment Banking (1992-1995) and subsequently as Director in Equity Capital Markets (1995-2002). Since her return to Italy, Ms. Calloni has been carrying out investment activities in private companies operating in renewables, fintech and tech sectors. She also actively provides financial advisory services – with a focus on capital raising and M&A processes – to portfolio companies. Currently, Ms. Calloni also serves on the board of directors of Industrie De Nora, which operates in the field of sustainable technologies for electrochemical industrial processes and water treatment, and Pininfarina, which is active in the automotive and industrial design sector. In the recent past, she served as an independent member of the Board of Directors of Credito Valtellinese (2019-2021) and CAD IT (2019-2021) and as executive board member of Deus Technology (2018-2019).

Guido Guidi has 35 years of experience in the pharmaceutical industry. He received his medical training at the University of Milan, where he obtained his MD in 1979. He continued his specialized training in Immunology and Allergology, as well as in Rheumatology in Milan until 1989. In parallel, he served as a medical advisor for Smith Kline and Roussel UCLAF and was medical director at Sharper Italia (Roussel UCLAF Group) from 1986 to 1989.

Dr. Guidi was previously Head of Pharma Europe and Head of Oncology Europe at Novartis, where he was responsible for bringing various drugs from clinical development to market including Cosentryx, Entresto, Lucentis, Gilenya, Xolair, Ultibro, Sandostatin, Femara, Glivec and Jiakavi. While at Novartis, Guido originated and chaired the first edition of Bioupper, the Novartis accelerator for early-stage projects in Italy. He was also Chairman of the Novartis European Executive Committee and a member of the Innovation Management Board responsible for the Pharma division’s R&D program. He has also held different medical positions within Novartis, Sandoz, Roussel-UCLAF and GSK. Guido is currently Chairman, Co-Founder and Managing Partner of the technology transfer company AurorA-TT.

Mr. Zambeletti is an Independent Strategic and Financial Advisor in the Healthcare sector. During his 25-year career as an investment banker, Mr Zambeletti led the EMEA Healthcare Investment Banking team at JP Morgan for eight years before taking up the same position at Credit Suisse for a further five years. He is a Non-Executive Director of Faron (AIM), Nogra Pharma, The Meatless Farm, Buccuico Ltd., Afimmune and DS Biopharma. Mr Zambeletti started his career at KPMG as an auditor and received a BA in Business from Bocconi University in Milan, Italy.